Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations
49 patients around the world
Available in Brazil
This study aims to test the hypothesis that delivery of maximum therapy consisting of
lazertinib plus amivantamab plus chemotherapy as frontline treatment in patients with
recurrent/metastatic NSCLC with EGFR exon 19 or exon 21 mutations will be feasible, safe, and
will improve PFS compared to historical controls. If successful, this study may allow for the
estimation of efficacy and toxicity of a three drug regimen of amivantamab, lazertinib, and
pemetrexed and may support further evaluation of maximum therapy against osimertinib single
agent, lazertinib single agent, osimertinib plus chemotherapy, and/or lazertinib plus
amivantamab.